Farallon Capital Management Adds $59M in Immunovant, Inc. ($IMVT)

Editorial illustration for Immunovant, Inc. (IMVT)

Key Points

  • Farallon Capital Management changed its Immunovant, Inc. ($IMVT) stake by 12783.33% last quarter, boosting to 1,546,000 shares worth $59.57 million.
  • Wall Street's consensus rating on $IMVT is Buy and an average price target of $48.88.
  • $IMVT last traded around $38.53.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Farallon Capital Management increased its position in Immunovant, Inc. ($IMVT) by 12783.33% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,546,000 shares of Immunovant, Inc. after buying 1,534,000 shares during the quarter. Farallon Capital Management's holdings in Immunovant, Inc. were worth $59.57 million as of its most recent filing.

Immunovant, Inc. Stock Down 6.5%

Shares of Immunovant, Inc. ($IMVT) traded around $38.53 on Sunday, down 6.5% for the day.

Last price$38.53
Market cap$8.43B
Forward P/E-14.84
Beta0.81
52-week low$14.58
52-week high$45.42
50-day MA$40.22
200-day MA$30.15
Current ratio7.27
Quick ratio6.82

Immunovant, Inc. Earnings

EPS (ttm)-$2.81
Revenue (ttm)
Net margin0%
Return on equity-80.10%
Next earningsNov 9, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$48.88
High target$66
Low target$30
Analysts covering16

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersDurham, NC
CEODr. Eric Venker M.D., Pharm.D.
Employees315

Get Immunovant, Inc. alerts

New 13F filings, insider trades, and analyst moves on $IMVT, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.